Cardax

Cardax is a biopharmaceutical company focused primarily on developing pharmaceuticals for diseases driven by inflammation. The company also has a commercial business unit that markets ZanthoSyn®, an astaxanthin dietary supplement for inflammatory health.* CDX-101, the company's astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the company's zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. The safety and efficacy of the company's pharmaceutical candidates have not been directly evaluated in clinical trials or confirmed by the FDA. www.cardaxpharma.com